Circadian owns Vegenics
Thursday, 14 August, 2008
Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.
Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.
Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.
Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
